19:20:37 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-29 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2022-11-18 08:00:00

CS MEDICA ("CS MEDICA" or the "Company") hereby publishes its interim report for the period October 2021 - September 2022. The report is available as an attached document to this press release and on the Company's website (www.cs-medica.com). Below is a summary of the report.

Performance highlights fourth quarter (July 2022 - September 2022)
  • Net Sales for the year increased by 233% in Danish kroner compared to 2020/2021[1]. Net Sales in the fourth quarter increased by 311% in Danish kroner compared to the fourth quarter of 2020/2021[1]. Sales growth was mainly driven by export sales to the EU.
  • Within R&D, CS MEDICA initiated phase 3 development on all products, according to the new regulation MDR, biocompatibility tests, absorption tests and clinical trials on all medical device products.
  • Revenue expectation for the coming year is held at DKK 65 million, but with the majority in the latter half of the year.
  • As of September 30, 2022 cash and cash equivalents in the company amounted to tDKK 2.933 (tDKK 9.996).
  • At the end of the period, CS MEDICA's equity/assets ratio ­­­was 89% (88%)

[image]

Significant events during the fourth quarter (July 2022 - September 2022)

 

Significant events after the period

[1] The Company are currently applying the IFRS standards in their financial accounts to meet the requires following their long-term goal of moving to the main market.  As the cost and revenue recognition criteria between ÅRL (applied in this report) and IFRS vary, there may be changes in revenue, cost and other recognitions in the upcoming Annual Report, submitted according to IFRS standards.